The costs of alcoholism

Journal of Mental Health

Volumn 14, Issue 4, 2005, Pages 321-330

  Simon, Judit ^a,b   Patel, Anita ^a   Sleed, Michelle ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Alcohol abuse; Alcohol dependence; Cost effectiveness; Cost of illness; Economic burden

Indexed keywords

4 HYDROXYBUTYRIC ACID; ACAMPROSATE; ANTIDEPRESSANT AGENT; CITALOPRAM; DISULFIRAM; FLUVOXAMINE; LISURIDE; LITHIUM; MOOD STABILIZER; NALMEFENE; NALTREXONE; OPIATE ANTAGONIST;

ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; ALCOHOLISM; BEHAVIOR THERAPY; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DEPENDENCE TREATMENT; ECONOMIC EVALUATION; GERMAN FEDERAL REPUBLIC; HEALTH CARE COST; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; META ANALYSIS; MOTIVATION; PATIENT COUNSELING; PSYCHOLOGICAL AND PSYCHIATRIC PROCEDURES, TECHNIQUES AND CONCEPTS; PSYCHOTHERAPY; REVIEW; SOCIOECONOMICS; SPAIN; SYSTEMATIC REVIEW; UNITED STATES;

EID: 24944478634     PISSN: 09638237     EISSN: None     Source Type: Journal    
DOI: 10.1080/09638230500195130     Document Type: Review

References (34)

1. Agosti, V. (1994). The efficacy of controlled trials of alcohol misuse treatments in maintaining abstinence: A meta-analysis. International Journal of the Addictions, 29, 759-769.
2. Annemans, L., Vanoverbeke, N., Tecco, J., & D'Hooghe, D. (2000). Economic evaluation of Campral (Acamprosate) compared to placebo in maintaining abstinence in alcohol-dependent patients. European Addiction Research, 6, 71-78.
3. Brecht, J. G., Poldrugo, F., & Schädlich, P. K. (1996). Alcoholism: The cost of illness in the Federal Republic of Germany. Pharmacoeconomics, 10, 484-493.
4. Centers for Disease Control and Prevention (1990). Perspectives in disease prevention and health promotion. Alcohol-related mortality and years of potential life lost. Morbidity and Mortality Weekly Report, 39, 173-178.
5. Cisler, R., Holder, H. D., Longabaugh, R., Stout, R. L., & Zweben, A. (1998). Actual and estimated replication costs for alcohol treatment modalities: Case study from Project MATCH. Journal of Studies on Alcohol, 59, 503-512.
6. Coyle, D., Godfrey, C., Hardman, G., & Raistrick, D. (1997). Costing substance misuse services. Addiction, 92, 1007-1015.
7. Foster, R. H., & McClellan, K. J. (1999). Acamprosate: pharmacoeconomic implications of therapy. Pharmacoeconomics, 16, 743-755.
8. Gatch, M. B., & Lal, H. (1998). Pharmacological treatment of alcoholism. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 22, 917-944.
9. Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999). Pharmacological treatment of alcohol dependence: A review of the evidence. Journal of the American Medical Association, 281, 1318-1325.
10. Goodman, A. C., Nishiura, E., & Humphreys, R. S. (1997). Cost and usage impacts of treatment initiation: a comparison of alcoholism and drug abuse treatments. Alcoholism: Clinical & Experimental Research, 21, 931-938.
11. Gossop, M. (1995). The treatment mapping survey; a descriptive study of drug and alcohol treatment responses in 23 countries. Drug & Alcohol Dependence, 39, 7-14.
12. Harwood, H. J., Fountain, D., & Livermore, G. (1998). Economic costs of alcohol abuse and alcoholism. Recent Developments in Alcoholism, 14, 307-330.
13. Hayashida, M., Alterman, A. I., McLellan, A. T., O'Brien, C. P., Purtill, J. J., Volpicelli, J. R., et al. (1989). Comparative effectiveness and costs of inpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. New England Journal of Medicine, 320, 358-365.
14. Holder, H. D. (1987). Alcoholism treatment and potential health care cost saving. Medical Care, 25, 52-71.
15. Holder, H. D., Longabaugh, R., Miller, W. R., & Rubonis, A. V. (1991). The cost effectiveness of treatment for alcoholism: A first approximation. Journal of Studies on Alcohol, 52, 517-539.
16. Holder, H. D., & Blose, J. O. (1992). The reduction of health care costs associated with alcoholism treatment: A 14-year longitudinal study. Journal of Studies on Alcohol, 53, 293-302.
17. Holder, H. D., Cisler, R. A., Longabaugh, R., Stout, R. L., Treno, A., & Zweben, A. (2000). Alcoholism treatment and medical care costs from Project MATCH. Addiction, 95, 999-1013.
18. Howard, M. O., McGuffin, R. W., Saxon, A. J., Sloan, K. L., & Walker, R. D. (1996). Clinical issues related to the costs of alcoholism. Pharmacoeconomics, 9, 134-145.
19. Long, C. G., Williams, M., & Hollin, C. R. (1998). Treating alcohol problems: A study of programme effectiveness and cost effectiveness according to length and delivery of treatment. Addiction, 93, 561-571.
20. Mason, B. J. (2003). Acamprosate and naltrexone treatment for alcohol dependence: An evidence-based risk-benefit assessment. European Neuropsychopharmacology, 13, 469-475.
21. McCollister K. E., & French M. T. (2003) The relative contribution of outcome domains in the total economic benefit of addiction interventions: A review of first findings. Addiction, 98, 1647-1659.
22. McLellan, A. T., & Hunkeler E. (1998). Patient satisfaction and outcomes in alcohol and drug abuse treatment. Psychiatric Services, 49, 573-575.
23. McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000). Drug dependence, a chronic medical illness. Journal of the American Medical Association, 284, 1689-1695.
24. Moncini, M., Masini, E., Gambassi, F., & Mannaioni, P. F. (2000). Gamma-hydroxybutyric acid and alcohol-related syndromes. Alcohol, 20, 285-291.
25. Office of Population Censuses and Surveys (1995). The prevalence of psychiatric morbidity among adults living in private households in Great Britain. London: HMSO.
26. Palmer, A. J., Neeser, K., Weiss, C., Brandt, A., Comte, S., & Fox, M. (2000). The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol and Alcoholism, 35, 478-492.
27. Parthasarathy, S., Weisner, C., Hu, T. W., & Moore, C. (2001). Association of outpatient alcohol and drug treatment with health care utilization and cost: revisiting the offset hypothesis. Journal of Studies on Alcohol, 62, 89-97.
28. Sass, H., Soyka, M., Mann, K., & Zieglgansberger, W. (1996). Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry, 53, 673-680
29. Schädlich, P. K., & Brecht, J. G. (1998). The cost effectiveness of Acamprosate in the treatment of alcoholism in Germany: Economic evaluation of the prevention of relapse with acamprosate in the management of alcoholism (PRAMA) study. Pharmacoeconomics, 13, 719-730.
30. Schmidt, L. G., Dufeu, P., Kuhn, S., & Rommelspacher, H. (1994). Relapse prevention in alcoholics with an anticraving drug treatment: first results of the Berlin Study. Pharmacopsychiatry, 27 (Suppl.), 1-3.
31. Srisurapanont, M., & Jarusuraisin, N. (2001). Opioid antagonists for alcohol dependence (Cochrane Review). In: The Cochrane Library, Issue 4, Oxford: Update Software.
32. Weisner, C., Mertens, J., Parthasarathy, S., Moore, C., Hunkeler, E. M., Hu, T., & Selby, J. V. (2000). The outcome and cost of alcohol and drug treatment in an HMO: Day hospital versus traditional outpatient regimens. Health Services Research, 35, 791-812.
33. West, S. L., Garbutt, J. C., Carey, T. S. et al. (1999). Pharmacotherapy for alcohol dependence. AHCPR Publication No. 99-E004, Rockville, MD, USA.
34. Whitworth, A. B., Fisher, F., Lesch, O. M., Nimmerrichter, A., Oberbauer, H., Platz, F., et al. (1996). Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet, 347, 1438-1442